Marizyme

Marizyme, founded as a multi-technology biomedical company, is dedicated to the accelerated development and commercialization of medical technologies aimed at improving patient health outcomes. The company's core mission is to address urgent needs in acute care by leveraging its proprietary system of proteolytic enzymes, ProteomeX. Marizyme focuses on developing therapies that can reduce high mortality rates and healthcare costs associated with acute conditions. Their market focus includes hospitals and healthcare providers seeking innovative solutions for critical care.

Notable figures affiliated with Marizyme include its team of biomedical experts and strategic investors who support its mission of transforming acute care. Key achievements include the acquisition and development of ProteomeX technology, positioning Marizyme as a leader in enzyme-based therapeutic solutions. The company has made significant strides in advancing its product candidates, contributing to improved patient outcomes and setting new standards in the acute care sector.